Does Moderate Physical Activity in Hemodialysis Patients Reduce Inflammation?

Does Moderate Physical Activity in Chronic Hemodialysis Patients Reduce Inflammation Via Inhibition of Proinflammatory Monocyte Activity?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00893165

Enrollment

Registered

2009-05-05

Start date

2010-01-31

Completion date

2011-12-31

Last updated

2012-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage Renal Disease, Hemodialysis

Keywords

inflammation, cardiovascular disease

Brief summary

The purpose of this study is to observe a potential benefit of moderate physical activity by using bed mounted cycles during hemodialysis treatment sessions on inflammatory markers in the blood of patients with end-stage renal disease (ESRD).

Detailed description

Patients with ESRD on chronic hemodialysis patients frequently have elevated markers of inflammation (e.g., serum CRP values) and accumulation of proinflammatory monocyte populations in the circulation. The level of inflammation is highly predictive for cardiovascular disease and mortality. Physical activity has been shown to improve dialysis efficacy by improving the elimination of retention solutes. In healthy individuals, sports activity influences inflammatory immune parameters. The study will observe the influence of moderate physical activity (using a bed mounted cycle for 30min during dialysis thrice weekly) on circulating monocyte subpopulations and inflammatory proteins over a 9 month period in 16 chronic hemodialysis patients.

Interventions

BEHAVIORALmoderate physical activity

bed mounted cycles for physical activity for 30 min during each hemodialysis session

Study design

Observational model

CASE_CROSSOVER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* chronic hemodialysis treatment for at least three months * three dialysis sessions per week * good general clinical condition * stable hemodynamics during the most recent three dialysis sessions

Exclusion criteria

* conditions making the patient unable to use the bed mounted cycle (amputations, joint disease etc) * clinically obvious acute infections * active malignancy * pathologic results of spiroergometry or echocardiography that imply an elevated risk of participation * myocardial infarction within the last 12 weeks * uncontrolled arterial hypertension * uncontrolled diabetes mellitis with frequent hypoglycemia * unability to understand and consent the protocol

Design outcomes

Primary

Measure	Time frame
Composition of monocyte subpopulations as defined by CD14 and CD16 expression	6 months

Secondary

Measure	Time frame
Serum CRP values	6 months
Dialysis quality (kt/V, URR)	6 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026